Picking W L, Smith C, Petruci R, Scheffel J, Levich J D, Stetler D A
Department of Biochemistry and Genetics Program, University of Kansas, Lawrence 66045-2106.
J Rheumatol. 1990 Oct;17(10):1308-13.
Urine samples from patients with systemic lupus erythematosus (SLE) (n = 80), patients with rheumatoid arthritis (RA) (n = 21), and healthy controls (n = 36) were analyzed by radio-immunoassay (RIA) for anti-RNA polymerase I (RPI) antibodies. Significant levels of anti-RPI antibodies were detected in the urine of 46% of the patients with SLE but in only 19% of the patients with RA and in no sample from healthy individuals. The presence of anti-RPI antibodies in the urine was confirmed by demonstrating that IgG purified from the urine of patients with SLE was capable of inhibiting the transcriptional activity of RPI in vitro. If the quantity of anti-RPI antibodies excreted is related to disease activity, analysis of urine for these antibodies may be a useful alternative for the purpose of monitoring the progression of disease in individuals with SLE because of the ease by which the sample can be collected.
采用放射免疫分析法（RIA）对系统性红斑狼疮（SLE）患者（n = 80）、类风湿性关节炎（RA）患者（n = 21）及健康对照者（n = 36）的尿液样本进行抗RNA聚合酶I（RPI）抗体分析。在46%的SLE患者尿液中检测到显著水平的抗RPI抗体，而在RA患者中仅19%检测到，健康个体样本中均未检测到。通过证明从SLE患者尿液中纯化的IgG能够在体外抑制RPI的转录活性，证实了尿液中抗RPI抗体的存在。如果排泄的抗RPI抗体量与疾病活动相关，由于尿液样本易于采集，对这些抗体进行尿液分析可能是监测SLE患者疾病进展的一种有用替代方法。
